To understand what psilocybin does in the brain, it helps to follow the molecule from the moment it is swallowed to the receptors it eventually binds to. The pharmacology is well-established in its broad outlines, even where mechanistic details remain debated.
This article walks through that pharmacological journey in a way that does not assume a background in chemistry or neuroscience.
What Psilocybin Is
Psilocybin is a tryptamine — a class of organic compounds built around an indole ring with a side chain. The neurotransmitter serotonin is also a tryptamine, which is part of why psilocybin acts on the serotonin system in the brain. The structural similarity is the key to its activity.
Psilocybin itself is what pharmacologists call a “prodrug” — a compound that is not itself responsible for the biological effect but is converted in the body into the active substance. The active substance is psilocin, structurally very similar to psilocybin but with a hydroxyl group where psilocybin has a phosphate ester. The conversion happens almost immediately after ingestion, primarily in the gut and liver.
For practical purposes, what gets you high is psilocin. Psilocybin is just the form in which the compound exists in the mushroom and the form in which it gets into the body. The metabolic conversion is fast and reliable enough that the distinction is often glossed over, but it matters for understanding pharmacokinetics.
Absorption and Onset
Psilocybin is well-absorbed from the digestive tract. Onset of effects typically begins 20-60 minutes after oral ingestion on an empty stomach, with food in the stomach delaying onset somewhat. The acute effects peak roughly 90 minutes to 2 hours after ingestion and gradually decline over the following 4-6 hours. Most people report being substantially back to baseline 6-8 hours after a moderate dose.
The relatively long duration is a function of psilocin’s metabolism, which proceeds at a moderate pace through enzymes in the liver. The compound is eventually broken down primarily into psilocin glucuronide, a water-soluble metabolite that is excreted in urine. Most of an ingested dose is cleared within 24 hours.
Individual variation in onset, peak, and duration is substantial. Body size, metabolism, what is in the stomach, and individual variation in liver enzyme activity all affect the timeline. Two people taking the same dose can have quite different experiences in terms of timing alone.
Receptor Binding
Once in the bloodstream, psilocin crosses the blood-brain barrier and reaches its primary site of action in the central nervous system. That site is the family of serotonin receptors — particularly the 5-HT2A subtype, with secondary action on 5-HT2C and several others.
The 5-HT2A receptor is densely expressed in the cortex, particularly in the prefrontal cortex and other association areas. These are the brain regions involved in higher-order cognitive functions: planning, reflection, abstract thought, sense of self. Psilocin’s action on these receptors is what produces the characteristic perceptual, cognitive, and emotional effects of the experience.
Importantly, psilocin is an agonist at 5-HT2A — meaning it binds to the receptor and activates it, mimicking serotonin’s natural action but in a different pattern. The selectivity and the binding kinetics differ from serotonin’s, which is why the cellular consequences are different from what natural serotonin signaling produces.
What Activated 5-HT2A Receptors Do
Activation of 5-HT2A receptors on cortical neurons increases their excitability. The neurons fire more readily in response to inputs they would normally largely ignore. This is part of why psychedelic experiences often involve perceiving connections between things that ordinarily seem unrelated, or being struck by ordinary stimuli as unusually meaningful.
At the network level, 5-HT2A activation appears to disrupt the normal coordination patterns of major brain networks, particularly the default mode network — the constellation of regions that is most active during self-referential thought and mind-wandering. The default mode network’s coordinated activity is reduced under psilocybin, while communication between networks that ordinarily do not interact much increases.
These network-level changes are thought to underlie the subjective experiences that are characteristic of the state: dissolution of the ordinary sense of self, novel associative connections, altered perception of self in relation to environment.
Other Pharmacological Effects
Beyond the central effects, psilocin has peripheral effects mediated by serotonin receptors in other tissues.
Cardiovascular effects are mild but real: modest increases in heart rate and blood pressure are typical during the acute phase. These are generally well-tolerated by people without underlying cardiovascular disease but can be relevant for people with significant cardiac conditions.
Pupillary dilation is reliable and visible. Mild nausea is common in the early part of the experience, particularly with mushroom material that contains other compounds beyond psilocybin. Some people experience headaches the day after a session — these appear to be related to the cardiovascular effects and tend to resolve with hydration.
The 5-HT2B receptor — distinct from the 5-HT2A receptor that mediates the psychoactive effects — is also activated by psilocin to a modest degree. Chronic stimulation of 5-HT2B receptors has been associated with cardiac valvulopathy in other contexts (notably with the diet drug fenfluramine). For occasional therapeutic doses this is not a meaningful concern, but it is part of the safety analysis for repeated dosing patterns like microdosing.
Tolerance and Cross-Tolerance
Psilocybin produces rapid tolerance. A second dose taken within 24 hours of the first will typically produce a substantially weaker effect; doses on consecutive days produce minimal effect after the first. The tolerance is thought to involve down-regulation of 5-HT2A receptors in response to acute activation.
Cross-tolerance exists with other classic psychedelics — LSD, mescaline, DMT — that act on the same receptor system. Someone who has recently taken LSD will find that a psilocybin dose produces a weaker than usual effect, and vice versa.
The tolerance dissipates over days; full sensitivity typically returns within a week to ten days.
What Pharmacology Does and Does Not Explain
Pharmacology can describe what the molecule does at the level of receptor binding and network activity. It is genuinely informative about why the experience has certain general features — the visual changes, the duration, the sense of altered self — and about what the relevant safety considerations are.
What pharmacology does not explain is why the specific content of psilocybin experiences varies so substantially between people, sessions, and contexts. Two people with similar pharmacology can have very different experiences with the same dose. The mechanisms that translate altered cortical activity into specific subjective experience involve many factors — set, setting, prior life experience, expectation — that are not captured by the pharmacology alone.
This is part of why psilocybin research is unusual in psychiatry: the pharmacology sets the stage, but it does not fully determine the play.